STOCK TITAN

ParkerVision (PRKR) registers 16.8M shares; CEO/CFO options extended

(Neutral)
(Neutral)
Form Type
424B3

Rhea-AI Filing Summary

ParkerVision, Inc. registers 16,809,295 shares of Common Stock for resale under a prospectus supplement dated April 27, 2026.

The supplement states the 16,809,295 shares consist of convertible-note conversions, prior private placements, shares issued for services and payables, and warrants, and that the company will not receive proceeds from selling stockholders. The company may receive up to $3,900,000 if Aspire and Tailwinds warrants are exercised for cash; any proceeds are expected to be used for general working capital and corporate purposes.

Separately, the company disclosed a Compensation Committee action dated April 22, 2026 extending the expiration dates of outstanding options for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029, which will result in an expected one-time non-cash share-based compensation charge of approximately $360,000.

Positive

  • None.

Negative

  • None.

Insights

Option term extensions preserve award value but raise governance questions on timing and disclosure.

The Compensation Committee approved extensions for fully vested, outstanding nonqualified options held by the CEO (2,660,000 options) and CFO (870,550) to August 7, 2029. The only change was the expiration date; exercise price and vesting were unchanged.

Key dependencies include shareholder approval policies (if any), disclosure adequacy, and whether extensions follow a consistent board policy. Future filings should show the charge and any related policy language; timing of financial recognition is tied to the company’s accounting treatment disclosed in its periodic reports.

The expected $360,000 non-cash charge is modest relative to typical equity modifications but will affect reported share-based compensation expense.

The company expects to record an approximate one-time non-cash share-based compensation charge of $360,000 related to the option extension. No new securities were issued and no other option terms changed.

Financial statement impact will appear in the period the modification is recognized; cash flow is unaffected. Watch the next periodic report for the precise charge classification and any footnote detail on valuation assumptions used to compute the modification cost.

Registered shares 16,809,295 shares Prospectus Supplement dated April 27, 2026
Potential warrant proceeds $3,900,000 If Aspire and Tailwinds warrants exercised for cash
Aspire warrant shares 5,000,000 shares Five-year warrant with $0.74 exercise price
Tailwinds warrant shares 200,000 shares Three-year warrant with $1.00 exercise price
CEO options 2,660,000 options Extended to August 7, 2029; exercise price $0.171
CFO options 870,550 options Extended to August 7, 2029; exercise price $0.171
One-time share-based charge $360,000 Expected non-cash charge for option modification
Prospectus Supplement regulatory
"This Prospectus Supplement relates to the prospectus dated April 28, 2020"
A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.
Convertible promissory note financial
"issuable upon conversion of, and for the payment of interest... a convertible promissory note dated September 13, 2019"
A convertible promissory note is a loan a company takes now that can later be turned into shares instead of being repaid in cash. Think of it as lending money with the option to accept ownership in the business down the road; that matters to investors because it affects who gets paid first, how much ownership existing shareholders keep, and the company’s future valuation and cash needs. Terms such as conversion price, interest and maturity determine the financial impact.
Warrant agreement financial
"issued pursuant to a warrant agreement with Aspire Capital Fund LLC"
A warrant agreement is the legal document that lays out the rules for stock warrants — special certificates that let their holder buy company shares at a set price within a certain time. It explains how and when warrants can be exercised, transferred, changed, or canceled, and what happens to them if the company raises money or is sold; investors care because these terms affect potential future ownership, dilution of shares, and the real value of the warrants.
Nonqualified stock options compensation
"modified certain outstanding nonqualified stock options held by its Chief Executive Officer"
A nonqualified stock option is a company-issued right that lets an employee or contractor buy shares later at a preset price, like a coupon to purchase stock regardless of the market price. It matters to investors because when the option is used the recipient owes ordinary-income tax on the difference between market and preset price, which affects the holder’s financial decisions and can change the company’s share count and reported expenses.
Share-based compensation charge accounting
"expects to record a one-time non-cash share-based compensation charge of approximately $360,000"
Offering Type resale/secondary
Use of Proceeds General working capital and corporate purposes (proceeds only if warrants exercised)

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Learn about SEC filing dates

FAQ

What shares does PRKR register in the prospectus supplement?

The supplement registers 16,809,295 shares of common stock for resale. These include convertible-note conversions, private placement shares, shares issued for services/payables, and warrants.

Will ParkerVision receive money from the registered resale of shares?

The company will not receive proceeds from sales by the selling stockholders. If Aspire and Tailwinds warrants are exercised for cash, the company may receive up to $3,900,000.

What are the warrant exercise terms referenced in the supplement?

The Aspire warrant covers up to 5,000,000 shares at an exercise price of $0.74; the Tailwinds warrant covers up to 200,000 shares at $1.00, subject to adjustment.

What option changes did ParkerVision disclose on Form 8-K?

The Compensation Committee extended option expirations for the CEO (2,660,000 options) and CFO (870,550 options) from August 7, 2026 to August 7, 2029; exercise prices and vesting remained unchanged.

How will the option modification affect ParkerVision’s financials?

The company expects a one-time non-cash share-based compensation charge of approximately $360,000. The charge will be reflected in the period the modification is recognized in the financial statements.

Filed pursuant to Rule 424(b)(3)

Registration No. 333-237762

 

PROSPECTUS SUPPLEMENT No. 73

(to Prospectus dated April 28, 2020)

 

PARKERVISION, INC.

16,809,295 Shares of Common Stock

 

This Prospectus Supplement relates to the prospectus dated April 28, 2020, as amended and supplemented from time to time (the “Prospectus”), which permits the resale by the selling stockholders listed in the Prospectus of up to 16,809,295 shares of our common stock, par value $0.01 per share (“Common Stock”) consisting of (i) up to 4,961,538 shares of Common Stock issuable upon conversion of, and for the payment of interest from time to time at our option, for a convertible promissory note dated September 13, 2019 which has a fixed conversion price of $0.10 per share and convertible promissory notes dated January 8, 2020 which have a fixed conversion price of $0.13 per share (the “Notes”), (ii) an aggregate of 3,907,331 shares of Common Stock issued pursuant to securities purchase agreements dated January 9, 2020, January 15, 2020, March 5, 2020 and March 19, 2020, (iii) an aggregate of 2,740,426 shares of Common Stock issued as payment for services and repayment of short-term loans and other accounts payable, including interest, (iv) up to 5,000,000 shares of Common Stock issuable upon exercise of a five-year warrant with an exercise price of $0.74 per share, subject to adjustment and issued pursuant to a warrant agreement with Aspire Capital Fund LLC (“Aspire”) and (v) up to 200,000 shares of Common stock issuable upon exercise of a three-year warrant with an exercise price of $1.00 per share, subject to adjustment and issued pursuant to a warrant agreement with Tailwinds Research Group LLC (“Tailwinds”).

 

We will not receive proceeds from the sale of the shares of Common Stock by the selling stockholders. To the extent the Aspire and Tailwinds warrants are exercised for cash, we will receive up to an aggregate of $3,900,000 in gross proceeds. We expect to use proceeds received from the exercise of the Aspire and Tailwinds warrants, if any, for general working capital and corporate purposes.

 

This Prospectus Supplement is being filed to update and supplement the information previously included in the Prospectus with the information contained in our Current Report on Form 8-K filed with the Securities and Exchange Commission (the “SEC”) on April 27, 2026.  Accordingly, we have attached the 8-K to this prospectus supplement.  You should read this prospectus supplement together with the prospectus, which is to be delivered with this prospectus supplement.

 

Any statement contained in the Prospectus shall be deemed to be modified or superseded to the extent that information in this Prospectus Supplement modifies or supersedes such statement.  Any statement that is modified or superseded shall not be deemed to constitute a part of the Prospectus except as modified or superseded by this Prospectus Supplement.

 

This Prospectus Supplement should be read in conjunction with, and may not be delivered or utilized without, the Prospectus.

 

Our Common Stock is listed on the OTCQB Venture Capital Market under the ticker symbol “PRKR.” 

 

Investing in our securities involves a high degree of risk. See Risk Factors beginning on page 6 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities.

 

Neither the SEC nor any such authority has approved or disapproved these securities or determined whether this prospectus is truthful or complete. Any representation to the contrary is a criminal offense.

 

The date of this Prospectus Supplement is April 27, 2026.

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

______________

FORM 8-K

 

CURRENT REPORT

 

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported):April 22, 2026

 

PARKERVISION, INC.

(Exact Name of Registrant as Specified in Charter)

     

Florida

000-22904

59-2971472

(State or Other Jurisdiction of Incorporation)

(Commission File Number)

(IRS Employer Identification No.)

 

   

4446-1A Hendricks Avenue Suite 354, Jacksonville, Florida

32207

(Address of Principal Executive Offices)

(Zip Code)

 

(904) 732-6100

(Registrant’s Telephone Number, Including Area Code)

 

N/A

(Former Name or Former Address, if Changed Since Last Report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

   

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

   

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

   

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class

Trading Symbol

Name of Each Exchange on Which Registered

None

 

 

 

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter.

 

Emerging growth company   ☐

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.   ☐

 

 

 

 

Item 5.02(e) Compensatory Arrangements of Certain Officers

 

On April 22, 2026, the Compensation Committee of the Board of Directors (“Committee”) of ParkerVision, Inc. (the “Company”), approved the modification of certain outstanding nonqualified stock options held by its Chief Executive Officer, Jeffrey Parker, and its Chief Financial Officer, Cynthia French, in order to extend the expiration date of the options from August 7, 2026 to August 7, 2029 to preserve the intended long-term incentive value of the awards.

 

The modified options include 2,660,000 options awarded to Mr. Parker and 870,550 options awarded to Ms. French on August 7, 2019, with an exercise price of $0.171 per share and an original term of seven years. The options were fully vested as of the modification date and the Company expects to record a one-time non-cash share-based compensation charge of approximately $360,000 in connection with the modification of these awards.

 

The extension of the expiration date is the only modification made to these awards, and no changes were made to the exercise price, the number of shares subject to the awards, vesting status or any other terms of the awards. No additional securities were issued in connection with the modification.

 

 

 Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:

 

Exhibit

Description

104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

     

Dated: April 27, 2026

   
   

PARKERVISION, INC.

     
   

By /s/ Cynthia French

   

Cynthia French

   

Chief Financial Officer